---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-016616"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:41:24.953679+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCardia Q1 net loss narrows to $2.3M; CardiAMP HF 86% mortality reduction in subgroup

## Summary
- Q1 net loss $2.3M vs $3.5M YoY; revenue $55K; operating cash burn $1.5M (improved from $2.6M).
- CardiAMP HF interim: 86% relative risk reduction in mortality for elevated NTproBNP subgroup; final data Q4 2024.
- Confirmatory Phase III HF II trial activated Q1; 250-patient, >90% powered, enrollment goal 2 years.
- CardiALLO low dose cohort completed with no adverse events; partnership with StemCardia for Phase I/II.
- Morph-DNA steerable sheath FDA submission on track for Q2 2024; expected approval Q3 2024.

## SEC filing metadata
- accession: 0001437749-24-016616
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774924016616/0001437749-24-016616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774924016616/bcda20240513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-016616
- JSON: https://secwatch.observer/filing/0001437749-24-016616.json
- Plain text: https://secwatch.observer/filing/0001437749-24-016616.txt

## Key facts
- Earnings Releases
  BioCardia, Inc. reported first quarter of 2024 results: revenue approximately $55,000.
  - Period: first quarter of 2024
  - Revenue: approximately $55,000
  - Result: reported results
  source text: Revenues were approximately $55,000 for the three months ended March 2024, compared to approximately $64,000 for the three months ended March 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/925741/000143774924016616/0001437749-24-016616-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.